Products for Research Use Only
RegisterLogin

Lasofoxifene

CAT: 0804-HY-A0037-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-A0037-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lasofoxifene (CP-336156) is an orally active and selective estrogen receptor modulator (SERM) . Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis[1][2].
CAS Number
180916-16-9
Product Name Alternative
CP-336156
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Estrogen Receptor/ERR
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lasofoxifene.html
Purity
99.27
Solubility
DMSO : 9.09 mg/mL (ultrasonic; adjust pH to 4 with 1 M HCl)
Smiles
OC1=CC=C2[C@@H](C3=CC=C(OCCN4CCCC4)C=C3)[C@@H](C5=CC=CC=C5)CCC2=C1
Molecular Formula
C28H31NO2
Molecular Weight
413.55
Precautions
H302, H312, H332
References & Citations
[1]Lainé M, et al. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 May 12. 23 (1) :54. |[2]Andreano KJ, et al. The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. Mol Cancer Ther. 2020 Jul. 19 (7) :1395-1405. |[3]Andersson A, et al. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford) . 2016 Mar;55 (3) :553-63.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
NPJ Breast Cancer. 2022 Dec 14;8 (1) :130.|NPJ Breast Cancer. 2025 Nov 12;11 (1) :125.|bioRxiv. 2024 Jun 2:2024.05.28.596307.|Gynecol Oncol. 2019 Jul;154 (1) :199-206.|Mol Cancer Ther. 2020 Jul;19 (7) :1395-1405.

Alternative Products

CatalogName
281201-01Lasofoxifene
9680-25Lasofoxifene tartrate
MBS6096275-01Lasofoxifene Sulfate
TRC-L176490-1MGrac-Lasofoxifene
AR-L01216-01Lasofoxifene-d4

Popular Products